Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET study
Seven abstracts from across Jazz Pharmaceuticals plc’s neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego.
Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness and safety of low-sodium oxybate, Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, on key sleep outcomes and daytime symptoms, including excessive daytime sleepiness, in adults with narcolepsy or idiopathic hypersomnia (IH).
Notably, the results from DUET demonstrated statistically significant improvements from baseline to end of treatment in Epworth Sleepiness Scale scores, reduced sleep stage shifts, increased deep sleep, and reduced number of awakenings among adults with narcolepsy treated with Xywav.
In adults with IH, Xywav treatment also showed improvements in Epworth Sleepiness Scale and Idiopathic Hypersomnia Severity Scale scores.
Further, new patient-reported data from DUET demonstrated the association of Xywav treatment with improvements in daytime symptoms and functional impacts, including cognitive complaints, among adults with narcolepsy or IH.
Xywav is indicated for the treatment of excessive daytime sleepiness or cataplexy in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia.
“This year’s presentations at the AAN Annual Meeting reinforce our ongoing commitment to addressing debilitating neurological disorders, with limited or no treatment options including narcolepsy, idiopathic hypersomnia, and epilepsy,” says Sarah Akerman, MD, head of neuroscience global medical and scientific affairs of Jazz Pharmaceuticals, in a release. “We continually strive to expand our understanding, research, and capabilities in neuroscience through ongoing data generation for Xywav and Epidiolex to ensure patients’ lived experiences and needs are reflected holistically. By listening to our patients, their care teams, and leading industry experts, we aim to better address the unmet needs of those living with these difficult-to-treat conditions and ultimately help redefine possibilities for their lives.”
